Abeona Therapeutics Amends Loan Agreement with Avenue

An update from Abeona Therapeutics ( (ABEO) ) is now available.

On July 18, 2025, Abeona Therapeutics Inc. amended its Loan and Security Agreement with Avenue Venture Opportunities Fund, reducing the interest rate on its senior secured term loan from 13.5% to 11.75% per annum. As part of this amendment, Abeona issued warrants to Avenue and Avenue 2, allowing them to purchase up to 16,474 shares of common stock, with an exercise price of $6.07 per share. These warrants, which expire on July 18, 2030, can be exercised at any time and include provisions for anti-dilution adjustments.

The most recent analyst rating on (ABEO) stock is a Buy with a $27.50 price target. To see the full list of analyst forecasts on Abeona Therapeutics stock, see the ABEO Stock Forecast page.

Spark’s Take on ABEO Stock

According to Spark, TipRanks’ AI Analyst, ABEO is a Neutral.

Abeona Therapeutics faces substantial financial challenges with no current revenue and ongoing losses, impacting its overall score. However, the promising potential for FDA approvals and significant revenue opportunities from new therapies provide a positive outlook. Despite bullish technical signals, the high RSI suggests caution. The stock’s valuation remains unattractive due to its negative P/E ratio, but strong earnings call projections and adequate cash reserves offer some optimism for future performance.

To see Spark’s full report on ABEO stock, click here.

More about Abeona Therapeutics

Abeona Therapeutics Inc. operates in the biotechnology industry, focusing on developing gene and cell therapies. The company is engaged in creating treatments for rare genetic diseases, leveraging its expertise in gene therapy and regenerative medicine.

Average Trading Volume: 1,835,357

Technical Sentiment Signal: Buy

Current Market Cap: $320.2M

For an in-depth examination of ABEO stock, go to TipRanks’ Overview page.